Insider Selling: Cerus Co. (NASDAQ:CERS) Director Sells 20,000 Shares of Stock

Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt sold 20,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Cerus Stock Down 6.1 %

Cerus stock opened at $1.69 on Wednesday. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. Cerus Co. has a 1-year low of $1.38 and a 1-year high of $2.59. The firm’s fifty day simple moving average is $1.75 and its 200-day simple moving average is $1.91. The company has a market capitalization of $313.86 million, a P/E ratio of -15.36 and a beta of 1.24.

Hedge Funds Weigh In On Cerus

Several institutional investors have recently bought and sold shares of the stock. Secure Asset Management LLC acquired a new position in shares of Cerus during the 2nd quarter valued at about $27,000. Creative Planning grew its holdings in Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 8,411 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in Cerus during the second quarter valued at approximately $45,000. Intech Investment Management LLC bought a new position in shares of Cerus in the third quarter valued at approximately $71,000. Finally, Algert Global LLC acquired a new stake in shares of Cerus in the second quarter worth $97,000. 78.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered their target price on Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.